Health Care

How is AI Designing Novel Drugs?

2月 27, 2025

Guests: David Reese, EVP & Chief Technology Officer, Amgen; Gevorg Grigoryan, Co-founder & Chief Technology Officer, Generate:Biomedicines; Mike Nally, CEO, Generate:Biomedicines

Host: Yaron Werber, Biotechnology Analyst, TD Cowen

Yaron Werber conducts interviews and onsite tours with Amgen and Generate:Biomedicines to explore how AI and automation are revolutionizing every step of drug development; from discovery, to validation, to clinical trial enrollment, to manufacturing.

Importantly, while AI is a powerful tool, it is meant to amplify, not replace, human capabilities. We interviewed David Reese of Amgen, and Gevorg Grigoryan and Mike Nally of Generate:Biomedicines to discuss how their companies are using AI and automation to develop novel biologics at unprecedented speed and scale.

Disclaimer

This clip should not be copied, distributed, published or reproduced, in whole or in part. The information contained in this clip was obtained from publicly available sources, has not been independently verified by TD Securities, may not be current, and TD Securities has no obligation to provide any updates or changes. All price references and market forecasts are as of the date of clip. The views and opinions expressed in this clip are not necessarily those of TD Securities and may differ from the views and opinions of other departments or divisions of TD Securities and its affiliates. TD Securities is not providing any financial, economic, legal, accounting, or tax advice or recommendations in this clip. The information contained in this clip does not constitute investment advice or an offer to buy or sell securities or any other product and should not be relied upon to evaluate any potential transaction. Neither TD Securities nor any of its affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the statements or any information contained in this clip and any liability therefore (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed.